非小细胞肺癌患者的消融技术：单中心经验
Ablation techniques in non-small cell lung cancer patients: experience of a single center.
作者信息
Botsa E, Thanou I, Tavernaraki K, Thanos L
机构信息
First Pediatric Clinic, National and Kapodistrian University of Athens, Agia Sofia Children's Hospital, Athens, Greece.
Department of Medical Imaging and Interventional Radiology, Sotiria General Hospital for Chest Diseases, Athens, Greece.
出版信息
Hippokratia. 2022 Jul-Sep;26(3):105-109.
BACKGROUND
Percutaneous radiofrequency ablation (RFA) and microwave ablation (MWA) are well-established treatments for patients with non-small cell lung cancer (NSCLC). This study assessed the efficacy and safety of RFA and MWA performed on NSCLC patients.
MATERIAL AND METHODS
This retrospective study included one hundred twenty-four patients with NSCLC who underwent percutaneous ablation from November 2014 to November 2020 in the Department of Medical Imaging and Interventional Radiology of Sotiria General Hospital for Chest Diseases in Athens, Greece. Forty (stage IA) were treated with RFA, while 84 were treated with MWA (stages IA, IB, and IIA). All procedures were performed using the AMICA GEN radiofrequency and microwave generator. As a follow-up method, computed tomography was performed immediately after the procedure to evaluate the lesion's response and complications and one, three, six, and twelve months after the ablation.
RESULTS
All ablations were technically successful. The first-month follow-up revealed stage IIA residual tumors in eight patients. Local recurrence was detected one year after RFA in two of the 40 patients and thirteen of the 84 patients after MWA. Overall survival (OS) rates at one, two, and three years for stage IA NSCLC patients treated with ablation were 94 %, 73 %, 57 % for RFA, and 96 %, 75 %, and 62 % for MWA, respectively. In contrast, the OS for stages IB and IIA patients treated with MWA was 90 %, 66 %, and 51 % for the IB stage and 82 %, 62 %, and 48 % for the IIA stage, respectively. Fifteen percent of patients after RFA and 9.5 % after MWA experienced minor complications. Pneumothorax was documented in three patients after RFA and four after MWA. Post-ablation syndrome occurred in 15 % of RFA patients and 8.3 % of MWA patients. There were no major complications.
CONCLUSION
RFA and MWA have comparable efficacy and safety for patients in stage IA. MWA is an effective alternative treatment option for non-resectable IB or IIA stages NSCLC patients. HIPPOKRATIA 2022, 26 (3):105-109.
背景
经皮射频消融（RFA）和微波消融（MWA）是治疗非小细胞肺癌（NSCLC）患者的成熟方法。本研究评估了对NSCLC患者进行RFA和MWA的疗效和安全性。
材料与方法
这项回顾性研究纳入了2014年11月至2020年11月在希腊雅典索蒂里亚胸科疾病综合医院医学影像与介入放射科接受经皮消融的124例NSCLC患者。40例（IA期）接受RFA治疗，84例接受MWA治疗（IA期、IB期和IIA期）。所有手术均使用AMICA GEN射频和微波发生器进行。作为随访方法，术后立即进行计算机断层扫描以评估病变的反应和并发症，并在消融后1个月、3个月、6个月和12个月进行评估。
结果
所有消融手术在技术上均获成功。第一个月的随访发现8例患者存在IIA期残留肿瘤。40例接受RFA治疗的患者中有2例在术后1年出现局部复发，84例接受MWA治疗的患者中有13例出现局部复发。IA期NSCLC患者接受消融治疗后1年、2年和3年的总生存率（OS），RFA组分别为94%、73%、57%，MWA组分别为96%、75%和62%。相比之下，接受MWA治疗的IB期和IIA期患者的OS，IB期分别为90%、66%和51%，IIA期分别为82%、62%和48%。RFA术后15%的患者和MWA术后9.5%的患者出现轻微并发症。RFA术后有3例患者出现气胸，MWA术后有4例。RFA患者中有15%出现消融后综合征，MWA患者中有8.3%出现。未发生重大并发症。
结论
RFA和MWA对IA期患者具有相当的疗效和安全性。MWA是非可切除IB期或IIA期NSCLC患者的一种有效替代治疗选择。《希波克拉底》2022年，26（3）：105 - 109。
Zotero 插件